0000000001018737

AUTHOR

G. Anastasi

showing 6 related works from this author

Diet and Gallstones in Women of a Rural Town of Sicily

1997

To test the possible association between dietary factors and gallstones, we performed a case-control study on the dietary habits of 71 women with gallstones in a rural area of Sicily (mean age 63.2 years) and compared these with 142 women who did not have gallstones (mean age 63.6 years) selected at random from the same general population. The dietary questionnaire, based on data collected over 7 days, was carefully compiled by two dieticians specially trained for the study. The daily calorie intake was higher in the women with gallstones ( p= 0.006) and was equally distributed between fats, carbohydrates and proteins. The intakes of unsaturated fats ( p= 0.03), unrefined sugars ( p= 0.01) …

medicine.medical_specialtyDieticianseducation.field_of_studyNutrition and Dieteticsbusiness.industryCholesterolGallbladderPopulationPublic Health Environmental and Occupational HealthMedicine (miscellaneous)Gallstonesmedicine.diseaseGastroenterologychemistry.chemical_compoundNutrientmedicine.anatomical_structurechemistryInternal medicineEpidemiologymedicineRisk factorbusinesseducationFood ScienceDemographyJournal of Nutritional & Environmental Medicine
researchProduct

Neridronate prevents bone loss in patients receiving androgen deprivation therapy for prostate cancer.

2004

Today, androgen deprivation therapy is a cornerstone of treatment for advanced prostate cancer, although it presents important complications such as osteoporosis. Neridronate, a relatively new bisphosphonate, is able to prevent bone loss in patients with prostate cancer during androgen ablation. Introduction: Androgen-deprivation therapy (ADT) is a cornerstone of treatment for advanced prostate cancer. This therapy has iatrogenic complications, such as osteoporosis. The aim of our study was to evaluate the efficacy of neridronate, a relatively new bisphosphonate, to prevent bone loss during androgen ablation. Materials and Methods: Forty-eight osteoporotic patients with prostate cancer, tre…

musculoskeletal diseasesMalemedicine.medical_specialtyDeoxypyridinolineTime FactorsBicalutamideAntineoplastic Agents HormonalEndocrinology Diabetes and Metabolismmedicine.medical_treatmentOsteoporosisUrologyBone and BonesAndrogen deprivation therapychemistry.chemical_compoundProstate cancerAbsorptiometry PhotonBone DensityMedicineNeridronic acidHumansOrthopedics and Sports MedicineAmino AcidsAgedCholecalciferolTriptorelin PamoateDiphosphonatesbusiness.industryProstatic NeoplasmsAndrogen AntagonistsBisphosphonatemedicine.diseaseAlkaline PhosphataseAndrogen deprivation therapy; Bisphosphonates; Neridronate; Osteoporosis; Prostate cancer; Absorptiometry Photon; Aged; Alkaline Phosphatase; Amino Acids; Androgen Antagonists; Androgens; Antineoplastic Agents Hormonal; Bone Density; Bone and Bones; Calcium; Cholecalciferol; Diphosphonates; Humans; Male; Osteoporosis; Prostatic Neoplasms; Time Factors; Triptorelin Pamoate; SurgerySurgerychemistryAndrogensOsteoporosisCalciumbusinessCholecalciferolmedicine.drugJournal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
researchProduct

GLI INDICATORI DI WOLFF PER LA VALUTAZIONE DEL RISCHIO CLINICO

2009

INDICATORI DI WOLFF RISCHIO CLINICO
researchProduct

Preventing bone loss during androgen deprivation therapy for prostate cancer: Early experience with neridronate

2005

Abstract Objective: Androgen-deprivation therapy (ADT) is the usual treatment for locally advanced or metastatic prostate cancer. Osteoporosis is a common complication of ADT. The aim of our study was to evaluate the efficacy of neridronate, a relatively new bisphosphonate to prevent bone loss during androgen ablation. Methods: Sixty patients with prostate cancer and osteoporosis were enrolled and randomly assigned to 2 different treatment regimes: group A (30 patients) treated with maximum androgenic blockage (MAB), and group B (30 patients) treated with bicalutamide 150mg. Each group was divided in 2 subgroups A1–A2 and B1–B2. All patients received calcium and cholecalciferol supplements …

Malemusculoskeletal diseasesmedicine.medical_specialtyDeoxypyridinolineBone densityBicalutamideUrologymedicine.medical_treatmentOsteoporosisUrologyImmunoenzyme TechniquesTosyl CompoundsAndrogen deprivation therapyProstate cancerchemistry.chemical_compoundAbsorptiometry PhotonBone DensityNitrilesmedicineHumansNeridronic acidAnilidesTestosteroneAmino AcidsVitamin DChromatography High Pressure LiquidAgedAged 80 and overDiphosphonatesEstradiolbusiness.industryProstatic NeoplasmsAndrogen AntagonistsPhosphorusBisphosphonatemedicine.diseaseSurgeryTreatment OutcomechemistryParathyroid HormoneOsteoporosisCalciumDrug Therapy CombinationbusinessBiomarkersFollow-Up Studiesmedicine.drug
researchProduct

Interferon-?? Alone versus Interferon-?? plus Ribavirin in Patients with Chronic Hepatitis C Not Responding to Previous Interferon-?? Treatment

2000

Objective: To study the effects of monotherapy with leucocyte interferon-α (IFNα) versus IFNα + ribavirin in patients with chronic hepatitis C who were nonresponders to previous courses of recombinant or lymphoblastoid IFNα. Design and setting: This was a nonblind randomised study of outpatients at 3 centres in Palermo, Sicily, Italy. Patients and participants: We recruited 72 patients (48 males, 24 females), mean age 48.8 ± 6.6 years (range 31 to 63 years), with biopsy-proven chronic hepatitis C, predominantly genotype lb. Interventions: 24 patients (group A) received IFNα 6MU 3 times weekly for 6 months, and 48 patients (group B) received IFNα 6MU 3 times weekly + ribavirin 1200 mg/day fo…

Pharmacologymedicine.medical_specialtyCombination therapybusiness.industryRibavirinHepatitis C virusAlpha interferonGeneral Medicinemedicine.disease_causeGastroenterologydigestive system diseasesGroup Bchemistry.chemical_compoundchemistryInterferonInternal medicineAbsolute neutrophil countMedicinePharmacology (medical)businessAdverse effectBiotechnologymedicine.drugBioDrugs
researchProduct

Comparative responses to three different types of interferon-α in patients with chronic hepatitis C

1999

We investigated the efficacy and tolerability of three different types of interferon-alpha, administered with the same schedule to naive patients with chronic hepatitis C. One hundred and seven patients with histologically proven chronic hepatitis C were enrolled during a period of three years and randomly divided into three groups, to receive (a) leukocyte-interferon-alpha, 6 MU three times a week for 4 months, followed by 3 MU three times a week for 8 months (Group I); (b) recombinant-IFN-alpha-2a, with the same schedule (Group II); and (c) lymphoblastoid-IFN-alpha-N1, with the same schedule (Group III). All patients were followed-up for 6 months to evaluate the long-term response. The 'C…

Malemedicine.medical_specialtyTime FactorsCirrhosisAlpha interferonGastroenterologyStatistics Nonparametriclaw.inventionRandomized controlled triallawInternal medicinemedicineHumansAdverse effectAgedAnalysis of Variancebusiness.industryBiopsy NeedleRemission InductionInterferon-alphaGamma globulinGeneral MedicineHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseRecombinant ProteinsLiverTolerabilityInterferon Type IImmunologyFemaleAnalysis of variancebusiness
researchProduct